Today, Gubra A/S ("Company"), a company specializing in pre-clinical contract research services and peptide-based drug discovery within metabolic and fibrotic diseases, announced a collaboration with Amylyx Pharmaceuticals, Inc. ("Amylyx") for the development of a potential novel long-acting GLP-1 receptor antagonist. "We are pleased to partner with Amylyx to advance GLP-1 receptor antagonism research. This collaboration and development agreement is an example of leading pharmaceutical companies partnering with us for our machine learning-based peptide drug discovery platform. This is yet another testimony that our streaMLine platform can be used to develop peptide drug candidates for a very broad range of diseases," said Henrik Blou, CEO of Gubra. This collaboration brings together Gubra's expertise in quickly screening and identifying potent peptide therapeutics and Amylyx' expertise in developing novel therapies for communities with high unmet needs. At the end of the screening period, Gubra and Amylyx anticipate identifying a lead development candidate to enter Investigational New Drug (IND)-enabling studies. Amylyx then has the option to lead development once the drug peptide therapeutic has been identified. Under the agreement, Gubra will receive upfront and research payments and may receive more than $50 million in success-based development and commercialization milestones plus mid single digit royalties on worldwide net sales